imatinib mesylate has been researched along with Meningioma in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Avsar, T; Ceylan, D; Kilic, T; Oksal, MD; Tatarli, N | 1 |
| Ha, J; Jang, HM; Jung, DI; Jung, HW; Kim, JH; Lee, HC; Moon, JH; Sur, JH | 1 |
| Brandes, A; Eoli, M; Faedi, M; Franceschi, E; Lombardi, G; Mazza, E; Reni, M; Zanon, S | 1 |
| Abrey, LE; Aldape, K; Chang, SM; Cloughesy, TF; Deangelis, LM; Di Tomaso, E; Drappatz, J; Egorin, MJ; Fine, HA; Fink, K; Jain, RK; Kesari, S; Lamborn, KR; Ligon, KL; Mehta, M; Norden, AD; Prados, MD; Robins, HI; Stiles, CD; Wen, PY; Yung, WK | 1 |
| Coan, A; Desjardins, A; Drappatz, J; Friedman, HS; Gururangan, S; Herndon, JE; Lipp, ES; McLendon, RE; Norden, AD; Norfleet, JA; Peters, KB; Reardon, DA; Sampson, JH; Vredenburgh, JJ; Wen, PY | 1 |
| Hainfellner, J; Hassler, M; Horak, P; Marosi, C; Preusser, M; Wöhrer, A | 1 |
| Chen, TC; Gupta, V; Samuleson, CG; Su, S | 1 |
3 trial(s) available for imatinib mesylate and Meningioma
| Article | Year |
|---|---|
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2016 |
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tissue Distribution; Treatment Outcome | 2009 |
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Disease-Free Survival; Female; Humans; Hydroxyurea; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2012 |
4 other study(ies) available for imatinib mesylate and Meningioma
| Article | Year |
|---|---|
Antiangiogenic Molecules Suppressed Meningioma-Induced Neovascularization: A Corneal Angiogenesis Study.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Corneal Neovascularization; Imatinib Mesylate; Meningeal Neoplasms; Meningioma; Neovascularization, Pathologic; Rats; Receptor, Platelet-Derived Growth Factor beta; RNA | 2022 |
Imatinib mesylate plus hydroxyurea chemotherapy for cerebellar meningioma in a Belgian Malinois dog.
Topics: Animals; Benzamides; Cerebellar Neoplasms; Dog Diseases; Dogs; Fatal Outcome; Hydroxyurea; Imatinib Mesylate; Male; Meningioma; Piperazines; Prednisolone; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Retrospective Studies; Secondary Prevention; Statistics, Nonparametric; Treatment Outcome | 2012 |
Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Culture Techniques; Cell Line, Tumor; Drug Therapy, Combination; HIV Protease Inhibitors; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Meningeal Neoplasms; Meningioma; Mice; Mice, Nude; Microtubule-Associated Proteins; Nelfinavir; Neoplasm Proteins; Piperazines; Pyrimidines; Survivin | 2007 |